Ligand reported Q4 2025 total revenues and income of USD 59.7 million (+39%), including royalties of USD 50.5 million (+45%), Captisol sales of USD 7.8 million, and contract revenue and income of USD 1.3 million. Q4 GAAP net income was USD 44.8 million (USD 2.12 per diluted share), including a gain of USD 22.1 million from short-term investments; adjusted net income was USD 42.7 million (USD 2.02 per diluted share). Cash, cash equivalents and short-term investments were USD 733.5 million as of December 31, 2025. For FY 2025, total revenues and income were USD 268.1 million, with royalties of USD 161.0 million, Captisol sales of USD 40.2 million, and contract revenue and income of USD 66.9 million. FY GAAP net income was USD 124.5 million (USD 6.13 per diluted share), while core adjusted net income was USD 165.1 million (USD 8.13 per diluted share). Ligand reaffirmed 2026 guidance for total revenue of USD 245 million to USD 285 million, including royalty revenue of USD 200 million to USD 225 million, Captisol revenue of USD 35 million to USD 40 million, and contract revenue of USD 10 million to USD 20 million, with adjusted earnings per diluted share of approximately USD 8.00 to USD 9.00. Business highlights included China’s NMPA accepting Nuance Pharma’s NDA for Ohtuvayre for COPD maintenance treatment; Chugai planning a Japan NDA submission in 2026 for sparsentan (Filspari) in IgA nephropathy, and Travere reporting Q4 2025 U.S. Filspari net product sales of USD 103 million and an FDA action date of April 13, 2026 for its FSGS sNDA. Palvella reported positive Phase 3 SELVA topline results for Qtorin rapamycin in microcystic lymphatic malformations with an NDA planned for H2 2026, and the FDA granted Fast Track designation for Qtorin rapamycin in angiokeratomas. Sanofi updates included FDA priority review for a Tzield age-expansion sBLA with an April 29, 2026 target action date, and EU approval of Teizeild to delay onset of stage 3 type 1 diabetes in certain patients. CEO Todd Davis said Ligand exceeded its initial full-year adjusted EPS guidance by approximately 30%, citing performance across the royalty portfolio and the Zelsuvmi out-licensing and partner launch.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260700PRIMZONEFULLFEED9661767) on February 26, 2026, and is solely responsible for the information contained therein.
Comments